COReNAPCIN: The first Iranian Corona vaccine based on mRNA technology
COReNAPCIN is the first preventive vaccine made by ReNAP Company in Iran. ReNAP Knowledge-based company, with the support of the Vice-Presidency of Science, Technology and Knowledge-based Economy seeks to develop technical knowledge to produce new pharmaceutical and preventive products based on mRNA technology.
Vaccination plays a vital role in society’s immunity against diseases. Because of their adaptable structure, rapid manufacture, and great production efficiency, mRNA vaccines are preferred over other vaccines for mass production. If all the procedures are in place, it might only take a few weeks to design and produce an mRNA vaccine against a special antigen after its genetic code has been identified. As mRNA is created in a cell-free environment and in a laboratory setting, there is almost no limit to how much production can be increased as long as the necessary resources are available. The production method of other types of vaccines, including Inactivated vaccine, Adenovirus vaccine and Subunit vaccines, are more complicated and require more time compared to mRNA vaccine production.
The ability of mRNA vaccines to simultaneously produce a blood immune response and cellular immunity without the use of adjuvants in the vaccine formulation is their main advantage over other vaccines. Also, the speed and adaptability of the production of these vaccines allow for the rapid development of new vaccines in epidemic situations to stop the spread of the virus and human death.
Because mRNA vaccines are highly effective and have the potential for rapid production, they are an excellent choice in situations where viruses have the ability to genetically change and new strains of the virus are produced. By quickly producing vaccines against new variants, proper safety can be established in society.
Currently, in ReNAP, mRNA vaccine is produced against all high-risk strains of viruses such as the Brazilian, British, African and even Indian (Delta) strains, in addition to the Wuhan strain, which can be produced as soon as approval is received.
The first stage of the clinical trial and injection of the corona vaccine based on mRNA technology was carried out in the Imam Khomeini hospital, and this vaccine was tested on a male volunteer. It should be noted that the article related to this vaccine has been published innpj Vaccinesof Nature publications.
ارسال به دوستان